Enhancing immunotherapy through PD ‐ L 1 upregulation: the promising combination of anti‐ PD ‐ L 1 plus m TOR inhibitors
Molecular Oncology · 2025-01 · 19 (1) · 151-172
DOI: 10.1002/1878-0261.13699 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 11.09.2024. Verfasst von Anna Hernández-Prat und 16 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Programe, IMIM (Hospital del Mar Research Institute), Barcelona, Spain. Hauptthemen laut MEDLINE: B7-H1 Antigen, MTOR Inhibitors, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ISCIII/FEDER, Generalitat de Catalunya, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1 (PD‐1)/programmed cell death 1 ligand 1 (PD‐L1) pathway have transformed urothelial cancer (UC) therapy. The correlation between PD‐L1 expression and ICI effectiveness is uncertain, leaving the role of PD‐L1 as a predictive marker for ICI efficacy unclear. Among several ways to enhance the efficacy of ICI, trials are exploring combining ICIs with serine/threonine‐protein kinase mTOR (mTOR) inhibitors in different tumor types. The potential interaction between mTOR inhibitors and PD‐L1 expression in UC has not been well characterized. In our study, we investigated how phosphoinositide 3‐kinase (PI3K)/AKT/mTOR pathway inhibitors (TAK‐228, everolimus and TAK‐117) affect PD‐L1 expression and function in preclinical bladder cancer cell models. TAK‐228 increased cell surface levels of glycosylated PD‐L1 in all but one of the seven cell lines, regardless of baseline levels. TAK‐228 promoted the secretion of epidermal growth factor (EGF) and interferon‐β (IFNβ), both linked to PD‐L1 protein induction. Blocking EGF and IFNβ receptors reversed the TAK‐228‐induced PD‐L1 increase. Additionally, TAK‐228 enhanced IFN‐γ‐induced PD‐L1 expression and intracellular HLA‐I levels in some cells. TAK‐228‐treated bladder cancer cells exhibited resistance to the cytotoxic effects of peripheral blood mononuclear cells (PBMCs) and cluster of differentiation 8 (CD8)+ T cells. The addition of an anti‐PD‐L1 antibody diminished this resistance in T24 cells. Increased expression of PD‐L1 under TAK‐228 exposure was confirmed in patient‐derived explants (PDEs) treated ex vivo . These preclinical findings suggest that mTOR inhibition with TAK‐228 can increase PD‐L1 levels, potentially impacting the specific immune response against UC cells. This highlights the rationale for exploring the combination of mTOR inhibitors with ICIs in patients with advanced UC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Research Programe, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.
- Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain.
- Pathology Department, Hospital del Mar-CIBERONC, Barcelona, Spain.
- Pathology Department, IIS Fundación Jimenez Diaz-CIBERONC, Madrid, Spain.
- Immunity and Infection Group, IMIM (Hospital del Mar Research Institute)-CIBERONC, Barcelona, Spain.
- Universitat Autònoma de Barcelona, Spain.
ORCID-Profile: Anna Hernández-Prat, Joaquim Bellmunt
Förderung
- ISCIII/FEDER
- Generalitat de Catalunya
- Instituto de Salud Carlos III
- Pla Director d' Oncologia de Catalunya
- European Community through the Regional Development Funding Program
Zitieren
APA
Hernández-Prat, A., Rodriguez-Vida, A., Cardona, L., Qin, M., Arpí-Llucià, O., Soria-Jiménez, L., Menendez, S., Quimis, F. G., Galindo, M., Arriola, E., Salido, M., Juanpere-Rodero, N., Rojo, F., Muntasell, A., Albanell, J., Rovira, A., & Bellmunt, J. (2025). Enhancing immunotherapy through PD ‐ L 1 upregulation: the promising combination of anti‐ PD ‐ L 1 plus m TOR inhibitors. Molecular Oncology, 19(1), 151-172. https://doi.org/10.1002/1878-0261.13699
Vancouver
Hernández-Prat A, Rodriguez-Vida A, Cardona L, Qin M, Arpí-Llucià O, Soria-Jiménez L, et al. Enhancing immunotherapy through PD ‐ L 1 upregulation: the promising combination of anti‐ PD ‐ L 1 plus m TOR inhibitors. Molecular Oncology. 2025;19(1):151-172. doi:10.1002/1878-0261.13699
BibTeX
@article{HernndezPrat2025,
author = {Hernández-Prat, Anna and Rodriguez-Vida, Alejo and Cardona, Laura and Qin, Mengjuan and Arpí-Llucià, Oriol and Soria-Jiménez, Luis and Menendez, Sílvia and Quimis, Fabricio Gerel and Galindo, Miguel and Arriola, Edurne and Salido, Marta and Juanpere-Rodero, Nuria and Rojo, Federico and Muntasell, Aura and Albanell, Joan and Rovira, Ana and Bellmunt, Joaquim},
title = {Enhancing immunotherapy through PD ‐ L 1 upregulation: the promising combination of anti‐ PD ‐ L 1 plus m TOR inhibitors},
journal = {Molecular Oncology},
year = {2025},
volume = {19},
number = {1},
pages = {151--172},
doi = {10.1002/1878-0261.13699}
}
EUVIMED